Trevi Therapeutics (NASDAQ:TRVI) Price Target Cut to $18.00 by Analysts at Morgan Stanley

Trevi Therapeutics (NASDAQ:TRVI) had its price objective lowered by Morgan Stanley from $19.00 to $18.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

TRVI has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus lifted their target price on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Needham & Company LLC boosted their price target on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Finally, Leerink Partners raised their price objective on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $21.33.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $10.69 on Wednesday. Trevi Therapeutics has a 1 year low of $4.85 and a 1 year high of $14.39. The firm has a 50 day moving average price of $11.15 and a 200 day moving average price of $10.93. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -33.41 and a beta of 0.94.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. Sell-side analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Trading of Trevi Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC lifted its stake in shares of Trevi Therapeutics by 28.7% in the second quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock worth $24,549,000 after acquiring an additional 1,000,000 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Trevi Therapeutics during the 2nd quarter valued at approximately $1,238,000. Flputnam Investment Management Co. grew its stake in Trevi Therapeutics by 1,105.4% during the 3rd quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock valued at $9,590,000 after purchasing an additional 961,150 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Trevi Therapeutics during the 2nd quarter worth approximately $301,000. Finally, AXQ Capital LP purchased a new stake in Trevi Therapeutics during the 2nd quarter worth approximately $227,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics News Summary

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.